![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: SPECC1L |
Gene summary for SPECC1L |
![]() |
Gene information | Species | Human | Gene symbol | SPECC1L | Gene ID | 23384 |
Gene name | sperm antigen with calponin homology and coiled-coil domains 1 like | |
Gene Alias | CYTSA | |
Cytomap | 22q11.23 | |
Gene Type | protein-coding | GO ID | GO:0006996 | UniProtAcc | B2RMV2 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
23384 | SPECC1L | HTA11_3410_2000001011 | Human | Colorectum | AD | 6.20e-04 | 1.72e-01 | 0.0155 |
23384 | SPECC1L | HTA11_2487_2000001011 | Human | Colorectum | SER | 2.06e-20 | 7.04e-01 | -0.1808 |
23384 | SPECC1L | HTA11_1938_2000001011 | Human | Colorectum | AD | 2.12e-13 | 4.92e-01 | -0.0811 |
23384 | SPECC1L | HTA11_78_2000001011 | Human | Colorectum | AD | 1.26e-15 | 5.50e-01 | -0.1088 |
23384 | SPECC1L | HTA11_347_2000001011 | Human | Colorectum | AD | 1.29e-52 | 1.12e+00 | -0.1954 |
23384 | SPECC1L | HTA11_411_2000001011 | Human | Colorectum | SER | 1.97e-12 | 1.02e+00 | -0.2602 |
23384 | SPECC1L | HTA11_2112_2000001011 | Human | Colorectum | SER | 1.44e-16 | 1.20e+00 | -0.2196 |
23384 | SPECC1L | HTA11_3361_2000001011 | Human | Colorectum | AD | 1.15e-08 | 4.40e-01 | -0.1207 |
23384 | SPECC1L | HTA11_83_2000001011 | Human | Colorectum | SER | 5.34e-22 | 7.27e-01 | -0.1526 |
23384 | SPECC1L | HTA11_696_2000001011 | Human | Colorectum | AD | 3.47e-46 | 8.47e-01 | -0.1464 |
23384 | SPECC1L | HTA11_866_2000001011 | Human | Colorectum | AD | 9.67e-31 | 6.83e-01 | -0.1001 |
23384 | SPECC1L | HTA11_1391_2000001011 | Human | Colorectum | AD | 2.54e-24 | 6.46e-01 | -0.059 |
23384 | SPECC1L | HTA11_2992_2000001011 | Human | Colorectum | SER | 2.75e-16 | 9.04e-01 | -0.1706 |
23384 | SPECC1L | HTA11_5212_2000001011 | Human | Colorectum | AD | 4.71e-10 | 6.78e-01 | -0.2061 |
23384 | SPECC1L | HTA11_5216_2000001011 | Human | Colorectum | SER | 1.22e-05 | 6.23e-01 | -0.1462 |
23384 | SPECC1L | HTA11_546_2000001011 | Human | Colorectum | AD | 5.67e-10 | 5.48e-01 | -0.0842 |
23384 | SPECC1L | HTA11_7862_2000001011 | Human | Colorectum | AD | 1.84e-07 | 4.14e-01 | -0.0179 |
23384 | SPECC1L | HTA11_866_3004761011 | Human | Colorectum | AD | 4.49e-11 | 3.59e-01 | 0.096 |
23384 | SPECC1L | HTA11_4255_2000001011 | Human | Colorectum | SER | 1.32e-04 | 3.56e-01 | 0.0446 |
23384 | SPECC1L | HTA11_8622_2000001021 | Human | Colorectum | SER | 2.79e-02 | 3.40e-01 | 0.0528 |
Page: 1 2 3 4 5 6 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Cervix | N_HPV | ![]() |
Endometrium | AEH | ![]() |
Endometrium | EEC | ![]() |
Prostate | BPH | ![]() |
Prostate | Tumor | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SPECC1L | SNV | Missense_Mutation | c.365N>T | p.Thr122Ile | p.T122I | Q69YQ0 | protein_coding | deleterious(0.03) | benign(0.283) | TCGA-A2-A0T0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | SD | |
SPECC1L | SNV | Missense_Mutation | c.2568C>A | p.Asn856Lys | p.N856K | Q69YQ0 | protein_coding | tolerated(0.16) | benign(0.038) | TCGA-A8-A079-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | 5-fluorouracil | SD | |
SPECC1L | SNV | Missense_Mutation | c.1106N>T | p.Ser369Leu | p.S369L | Q69YQ0 | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-AC-A2QI-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | cytoxan | CR | |
SPECC1L | SNV | Missense_Mutation | novel | c.1345T>G | p.Leu449Val | p.L449V | Q69YQ0 | protein_coding | deleterious(0.02) | probably_damaging(0.999) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SPECC1L | SNV | Missense_Mutation | c.3035N>T | p.Ser1012Leu | p.S1012L | Q69YQ0 | protein_coding | deleterious(0.02) | probably_damaging(0.996) | TCGA-AO-A0J4-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
SPECC1L | SNV | Missense_Mutation | novel | c.1433N>G | p.Val478Gly | p.V478G | Q69YQ0 | protein_coding | tolerated(0.25) | benign(0) | TCGA-B6-A408-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD |
SPECC1L | SNV | Missense_Mutation | c.2135N>G | p.Ser712Cys | p.S712C | Q69YQ0 | protein_coding | deleterious(0.01) | possibly_damaging(0.89) | TCGA-BH-A0AZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | CR | |
SPECC1L | SNV | Missense_Mutation | c.109N>A | p.Gly37Arg | p.G37R | Q69YQ0 | protein_coding | deleterious(0.02) | benign(0.301) | TCGA-C8-A12T-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
SPECC1L | SNV | Missense_Mutation | c.3071A>C | p.Lys1024Thr | p.K1024T | Q69YQ0 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-E2-A14W-01 | Breast | breast invasive carcinoma | Male | >=65 | I/II | Chemotherapy | cytoxan | SD | |
SPECC1L | SNV | Missense_Mutation | novel | c.665N>A | p.Gly222Asp | p.G222D | Q69YQ0 | protein_coding | tolerated(0.09) | possibly_damaging(0.471) | TCGA-E9-A2JS-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cyclophosphamide | PD |
Page: 1 2 3 4 5 6 7 8 9 10 11 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
23384 | SPECC1L | NA | methotrexate | METHOTREXATE | 18539621 |
Page: 1 |